- ►annals.org [PDF] DA Ganz, KM Kuntz, GA Jacobson, J Avorn - Annals of internal medicine, 2000 - Am Coll Physicians David A. Ganz, BA; Karen M. Kuntz, ScD; Gretchen A. Jacobson, BA; and Jerry
Avorn, MD ... Background: 3-Hydroxy-3-methylglutaryl coenzyme A reductase
inhibitor (statin) therapy has proven efficacy in reducing the rate of ... Cited by 77 - Related articles - BL Direct - All 4 versions
- ►annals.org [PDF] LA Prosser, AA Stinnett, PA Goldman, LW … - Annals of Internal Medicine, 2000 - Am Coll Physicians Ann Intern Med. 2000;132:769-779. For author affiliations, current addresses,
and contributions, see end of text. S everal large-scale, long-term clinical
trials eval- uating statin drugs (3-hydroxy-3-methylglutaryl coenzyme A ... Cited by 184 - Related articles - BL Direct - All 6 versions
J Tsevat, KM Kuntz, EJ Orav, MC Weinstein, … - American Heart Journal, 2001 - Elsevier Background The objective of this study was to assess the cost-effectiveness of
pravastatin therapy in survivors of myocardial infarction with average
cholesterol levels. Methods We performed a cost-effectiveness analysis ... Cited by 65 - Related articles - BL Direct - All 9 versions
- ►health-economics.ca [PDF] SA Grover, L Coupal, S Paquet, H Zowall - Archives of Internal Medicine, 1999 - Am Med Assoc Methods A validated model based on data from the Lipid Research Clinics cohort
was used to estimate the benefits and cost-effectiveness of lipid modification
with 3-hydroxy-3-methylglutaryl–coenzyme A reductase inhibitors (statins) ... Cited by 69 - Related articles - BL Direct - All 6 versions
DM Huse, MW Russell, JD Miller, DF Kraemer, … - The American journal of cardiology, 1998 - Elsevier Currently, 6 hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors
(statins) are marketed in the United States (US). Given the wide variation in
the prices and efficacy of statins, formal cost-effectiveness analysis may ... Cited by 65 - Related articles - BL Direct - All 6 versions
MW Russell, DM Huse, JD Miller, DF Kraemer … - The Canadian journal of clinical pharmacology= …, 2001 - ncbi.nlm.nih.gov OBJECTIVE: To assess the cost effectiveness of 3-hydroxy-3-methylglutaryl
coenzyme A (HMG-CoA) reductase inhibitor therapy, particularly atorvastatin, in
primary and secondary prevention of coronary artery disease (CAD) in ... Cited by 24 - Related articles - BL Direct - All 4 versions
DE Hilleman, SM Heineman, PA Foral - Pharmacotherapy, 2000 - PPI We conducted a post hoc pharmacoeconomic analysis of a multicenter, open- label,
randomized, parallel-group, 8-week efficacy-safety comparison of five HMG-CoA
reductase inhibitors—atorvastatin, fluvastatin, lovastatin, pravastatin, ... Cited by 25 - Related articles - BL Direct - All 5 versions
E Attanasio, P Russo, SE Allen - Clinical therapeutics, 2001 - Elsevier Methods: We assessed the long-term maintenance cost of simvastatin versus
atorvastatin in terms of the cost of reducing low-density lipoprotein
cholesterol (LDL-C) levels to the recommended goals based on a previously ... Cited by 9 - Related articles - BL Direct - All 6 versions
S Perreault, C Levinton, J Le Lorier - The Canadian journal of clinical pharmacology= …, 2000 - ncbi.nlm.nih.gov BACKGROUND: Screening for hyperlipidemia is a substantial cost burden, as is its
treatment. The choice of 3-hydroxy-3-methylglutaryl coenzyme A reductase
inhibitors (statins) and the dose level may have significant implications ... Cited by 10 - Related articles - BL Direct - All 2 versions
WJ Elliott, DR Weir - American Journal of Health-System Pharmacy, 1999 - ASHP Abstract: The cost-effective- ness of each of the six hy-
droxymethylglutaryl–coenzyme A (HMG-CoA) reductase in- hibitors currently
available was studied. For a cohort of patients be- tween the ages of 60 ... Cited by 30 - Related articles - BL Direct - All 5 versions
